Medtronic Hit With Shareholder Suit Over Infuse Studies
Medical device maker Medtronic Inc. helped researchers downplay the risks and side effects of its Infuse bone graft product, causing its stock price to fall when the scheme was revealed, a...To view the full article, register now.
Already a subscriber? Click here to view full article